Erratum: Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel (Canadian Medical Association Journal (2006) 174, 12 (1715-1722) doi: 10.1503/cmaj.060664);Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 12, 2006, Pages 1715-1722

  Suh, Jung Won ^a   Koo, Bon Kwon ^a   Zhang, Shu Ying ^c   Park, Kyung Woo ^a   Cho, Joo Youn ^a   Jang, In Jin ^a   Lee, Dong Soon ^a   Sohn, Dae Won ^a   Lee, Myoung Mook ^b   Kim, Hyo Soo ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

^c Seoul National University Biomedical Research Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 3A5; ITRACONAZOLE; ANTITHROMBOCYTIC AGENT; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; ENZYME INHIBITOR; TICLOPIDINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; STENT; STROKE; SUDDEN DEATH; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INTERACTION; FAT EMBOLISM; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; EMBOLISM, CHOLESTEROL; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK FACTORS; THROMBOSIS; TICLOPIDINE;

EID: 33744968214     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060701     Document Type: Erratum

References (32)

1. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.
2. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
3. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002;106:1893-900.
5. Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responder among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 2003;89:783-7.
6. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13.
7. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-8.
8. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51.
9. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalized by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9.
10. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduced the ability of clopidogrel to inhibit platelet aggregation. Circulation 2003;107:32-7.
11. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166-71.
12. Wrighton SA, Schuetz EG, Thummel KE, et al. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000;32:339-61.
13. Evans WE, McLeod HL. Pharmacogenomics: Drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
14. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
15. Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP 3A4 and CYP3A5. Drug Metab Dispos 2003;31:938-44.
16. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003;76:1233-5.
17. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14:523-5.
18. Savi P, Labouret C, Delesque N, et al. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-83.
19. Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006;11:1977-86.
20. Yu KS, Cho JY, Jang IJ, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004;76:104-12.
21. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005;78:520-8.
22. Osanai T, Ohkubo T, Yasui N, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Br J Clin Pharmacol 2004;58:476-81.
23. Gawaz M, Ruf A, Pogatsa-Murray G, et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000;83:915-22.
24. Schomig A, Kastrati A, Mudra H, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out method for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
26. Flockhart DA, Tanus-Santos JE. Implication of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162:405-12.
27. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
28. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-95.
29. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002;12:331-4.
30. Hiratsuka M, Takekuma Y, Endo N, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002;58:417-21.
31. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002;30:1491-6.
32. Balram C, Zhou Q, Cheung YB, et al. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003;59:123-6.